The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides

References

• Byun JM, Shin DY, Hong J, et al. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. Cancer Med. 2018;7(3):831–841.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034–2040.
   PubMed Web of Science ®Google Scholar
• Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosom Cancer. 2005;44(2):194–203.
   PubMed Web of Science ®Google Scholar
• Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108(5):1724–1732.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Dingli D, Roy V, et al.; Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360–376.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Dispenzieri A, Chim CS, et al.; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–277.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. JCO. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Mohan M, Weinhold N, Schinke C, et al. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. Br J Haematol. 2020;189(1):67–71.
   PubMed Web of Science ®Google Scholar
• Chang H, Trieu Y, Qi X, et al. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains. Leuk Res. 2011;35(1):95–98.
   PubMed Web of Science ®Google Scholar
• Abramova TV, Obukhova TN, Mendeleeva LP, et al. Prognostic value of 1q21 amplification in multiple myeloma. Ter Arkh. 2017;89(7):32–38.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr, Haessler J, van Rhee F, et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 2007;137(6):530–536.
   PubMed Web of Science ®Google Scholar
• Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940–948.
   PubMed Web of Science ®Google Scholar
• Chen D, Zhou D, Xu J, et al. Prognostic value of 1q21 gain in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(3):e159–e164.
   PubMed Web of Science ®Google Scholar
• Li X, Chen W, Wu Y, et al. 1q21 Gain combined with high-risk factors is a heterogeneous prognostic factor in newly diagnosed multiple myeloma: a multicenter study in China. Oncology. 2019;24(11):e1132–e1140.
   Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet. Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Schmidt TM, Barwick BG, Joseph N, et al. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9(12):94.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949–1952.
   PubMed Web of Science ®Google Scholar
• Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159–170.
   PubMed Web of Science ®Google Scholar
• Yu W, Guo R, Qu X, et al. The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population. OncoTargets Therapy. 2016;9:295–302.
   PubMed Web of Science ®Google Scholar
• Shah V, Sherborne AL, Walker BA, et al.; on behalf of the NCRI Haemato-oncology CSG. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32(1):102–110.
   PubMed Web of Science ®Google Scholar
• Bock F, Lu G, Srour SA, et al. Outcome of patients with multiple myeloma and CKS1B gene amplification after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2016;22(12):2159–2164.
   PubMed Web of Science ®Google Scholar
• Du C, Mao X, Xu Y, et al. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib. Leuk Lymphoma. 2019:1–10.
   Google Scholar
• Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489–3495.
   PubMed Web of Science ®Google Scholar
• Bang SM, Kim YR, Cho HI, et al. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genet Cytogenet. 2006;168(2):124–132.
   PubMedGoogle Scholar
• Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998;12(6):960–969.
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543–556.
   PubMed Web of Science ®Google Scholar
• Hanamura I. Advances in multiple myeloma molecular biology research. Rinsho Ketsueki. 2019;60(9):1236–1242.
   PubMedGoogle Scholar
• Krishnan A, Nair SA, Pillai MR. Loss of cks1 homeostasis deregulates cell division cycle. J Cell Mol Med. 2010;14(1–2):154–164.
   PubMed Web of Science ®Google Scholar
• Haber DA, Settleman J. Cancer: drivers and passengers. Nature. 2007;446(7132):145–146.
   PubMed Web of Science ®Google Scholar
• Teoh PJ, Chung TH, Chng PYZ, et al. IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in 1q21(amp) multiple myeloma. Haematologica. 2020;105(5):1391–1404.
   PubMed Web of Science ®Google Scholar
• Marchesini M, Ogoti Y, Fiorini E, et al. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell. 2017;32(1):88–100. e106.
   PubMed Web of Science ®Google Scholar